Skip to content

Study of axillary reverse mapping by ICG to prevent upper extremity lymphedema after radical mastectomy

Study of axillary reverse mapping by ICG to prevent upper extremity lymphedema after radical mastectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000033797
Enrollment
Unknown
Registered
2020-06-12
Start date
2015-01-01
Completion date
Unknown
Last updated
2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Group 1:Axillary lymph node dissection
Group 2: Intraoperative retention of ARM lymph nodes and conventional axillary lymph node dissection

Sponsors

Affiliated Tumor Hospital of Shantou University Medical College
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Female patients; 2. Preoperative diagnosis of breast cancer by cytology, hollow core biopsy or excision biopsy; 3. Clinical examination of axillary lymph node positive or suspicious positive; 4. Clinically operable stage I and II breast cancer or operable stage IIIa at the initial diagnosis condition, or those who can be operated after the late stage neoadjuvant chemotherapy 5) Preoperative examination has no evidence of distant metastasis in clinical or imaging aspects (M0); 6. Those who have not undergone axillary surgery in the past; 7. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Have a history of SLNB or axillary surgery; 2. Breast cancer with multiple centers or multiple lesions; 3. Clinical and intraoperative sentinel lymph node biopsy found no axillary lymph node metastasis; 4. Have received radiotherapy or neoadjuvant chemotherapy in the breast area; 5. Inflammatory breast cancer; 6. Pregnancy; 7. Persons without personal freedom and independent civil capacity.

Design outcomes

Primary

MeasureTime frame
the feasibility of ARM using indocyanine green (ICG) ;the oncologic safety of ARM;

Countries

China

Contacts

Public ContactWu Jundong

Affiliated Tumor Hospital of Shantou University Medical College

wujun-dong@163.com+86 13829663428

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026